Celldex Therapeutics, Inc.
CLDX · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -1.21 | -0.40 | -0.81 | -0.72 |
| FCF Yield | -3.31% | -4.51% | -1.98% | -2.43% |
| EV / EBITDA | -21.13 | -19.25 | -29.93 | -43.24 |
| Quality | ||||
| ROIC | -9.66% | -8.85% | -7.43% | -6.58% |
| Gross Margin | 100.00% | 100.00% | 30.30% | 100.00% |
| Cash Conversion Ratio | 0.73 | 0.78 | 1.01 | 0.69 |
| Growth | ||||
| Revenue 3-Year CAGR | -15.86% | 21.17% | 33.88% | 43.88% |
| Free Cash Flow Growth | 17.73% | -63.61% | 39.27% | -84.86% |
| Safety | ||||
| Net Debt / EBITDA | 0.32 | 0.22 | 0.44 | 0.65 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 11.10 | 137.78 | -305.17 | -103.53 |